Neurogene Inc.
NGNEHealthcare|Biotechnology|US
$25.31
-0.34 (-1.33%)
DCF Value
$4.36
Tangible Book / Share
$9.63
Cash / Share
$9.99
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05898620 A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome | Rett Syndrome | P3 | Active | 33 | Single-blind | — |
| NCT05228145 Gene Therapy Study for Children With CLN5 Batten Disease | Neuronal Ceroid Lipofuscinosis CLN5 | P1P2 | Active | 6 | Open-label | — |
| NCT04659629 NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | Solid Tumor, Advanced Solid Tumor | P1 | Completed | 59 | Open-label | NL-201, Pembrolizumab Injection [Keytruda] |
| NCT03822650 A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5) | Ceroid Lipofuscinosis, Neuronal 5 | Completed | 37 | — | — | |
| NCT03853876 A Natural History Study of Aspartylglucosaminuria | Aspartylglucosaminuria, Aspartylglucosamidase (AGA) Deficiency | Terminated | 8 | — | — | |
| NCT03810508 A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J) | Charcot-Marie-Tooth Disease, Hereditary Motor and Sensory Neuropathy IV | Terminated | 21 | — | — |